Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Historical Controls For Epilepsy Studies To Be Considered By Advisory Cmte.

This article was originally published in The Pink Sheet Daily

Executive Summary

GlaxoSmithKline's Lamictal XR and several drugs in the pipeline could see their quest for monotherapy indications affected by what the Peripheral and Central Nervous System Drugs Advisory Committee decides.

You may also be interested in...



Lamictal XR's Monotherapy Claim May Spur More Historical Control Trials

GlaxoSmithKline’s anti-epileptic drug Lamictal XR gained approval for conversion to monotherapy without any post-marketing commitments despite concerns about the novel trial design employed for the application.

Lamictal XR's Monotherapy Claim May Spur More Historical Control Trials

GlaxoSmithKline’s anti-epileptic drug Lamictal XR gained approval for conversion to monotherapy without any post-marketing commitments despite concerns about the novel trial design employed for the application.

GSK Lamictal's New Warning On Aseptic Meningitis May Help Pfizer's Lyrica

On-patent antiepileptics may have another arrow in their promotional quivers after the now-generic lamotrigine gets a label update with reports of 40 cases of aseptic meningitis.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071732

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel